Head and neck cancer


Head and neck cancer trials open in South Yorkshire - includes brain and thyroid cancers

H&N040
IoN Is ablative radio-iodine necessary for low risk differentiated thyroid cancer patients
Information from UK Clinical Trials Gateway website about this trial (includes main eligibility criteria, accrual & contact information)
Information from CancerHelp UK website about this trial. CancerHelp UK is a free information service about cancer and cancer care for people with cancer and their families.

H&N045
A commercial trial for patients with advanced carcinoma of the Head and Neck

H&N046
COMPARE Trial Phase III randomised controlled trial Comparing Alternative Regimens for escalating treatment of intermediate and high-risk oropharyngeal cancer
Information from UK Clinical Trials Gateway website about this trial (includes main eligibility criteria, accrual & contact information)
Information from CancerHelp UK website about this trial. CancerHelp UK is a free information service about cancer and cancer care for people with cancer and their families.

H&N048
NIMRAD A randomised placebo-controlled trial of synchronous NIMorazole versus RADiotherapy alone in patients with locally advanced head and neck squamous cell carcinoma not suitable for synchronous chemotherapy or cetuximab
Information from UK Clinical Trials Gateway website about this trial (includes main eligibility criteria, accrual & contact information)
Information from CancerHelp UK website about this trial. CancerHelp UK is a free information service about cancer and cancer care for people with cancer and their families.

H&N049
Randomised, placebo-controlled, double-blind Phase 2 study of Patritumab (U3-1287) in combination with Cetuximab plus platinum-based therapy in first line setting in subjects with recurrent or metastatic squamous cell carcinoma of the head and neck
Information from UK Clinical Trials Gateway website about this trial (includes main eligibility criteria, accrual & contact information)

H&N051
DARS – A Phase III randomised multicentre study of dysphagia optimised intensity modulated radiotherapy (Do-IMRT) versus standard intensity modulated radiotherapy (S-IMRT) in head and neck cancer
Information from UK Clinical Trials Gateway website about this trial (includes main eligibility criteria, accrual & contact information)

MSS012
Select-d: Anticoagulation therapy in selected cancer patients at risk of recurrence of venous thromboembolism
Information from CancerHelp UK website about this trial. CancerHelp UK is a free information service about cancer and cancer care for people with cancer and their families.
Information from UK Clinical Trials Gateway website about this trial (includes main eligibility criteria, accrual & contact information)

MSS015
SPIRE SGI-110 to potentiate platinum response: a phase Ib/IIa open label clinical trial combining SGI-110 with cisplatin and gemcitabine chemotherapy
Information from CancerHelp UK website about this trial. CancerHelp UK is a free information service about cancer and cancer care for people with cancer and their families.
Information from UK Clinical Trials Gateway website about this trial (includes main eligibility criteria, accrual & contact information)

XXX095
ChOPIN Chemoprevention of premalignant intestinal neoplasia incorporating inherited predisposition of neoplasia (IPOD) analysis of genomic DNA from AspECT and BOSS clinical trials. It also incorporates patients undergoing genomic assessment independent of the AspECT and BOSS trials.
Information from CancerHelp UK website about this trial. CancerHelp UK is a free information service about cancer and cancer care for people with cancer and their families.

XXX130
NBT - National Brain Tumour Study
(On hold for recruitment)
Information from CancerHelp UK website about this trial. CancerHelp UK is a free information service about cancer and cancer care for people with cancer and their families.

XXX155
CAPRELSA European, observational, prospective study to evaluate the benefit/risk of Vandetanib (CAPRELSA) 300mg in RET mutation negative and RET mutation positive patients with symptomatic, aggressive, sporadic, unresectable, locally advanced/metastatic medullary thyroid cancer (MTC)
Information from UK Clinical Trials Gateway website about this trial (includes main eligibility criteria, accrual & contact information)